This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spruck, C. Articles by Reed, S. I. Search for Related Content PubMed PubMed Citation Articles by Spruck, C. Articles by Reed, S. I.

Detection of Low Molecular Weight Derivatives of Cyclin E1 Is a Function of Cyclin E1 Protein Levels in Breast Cancer

¹ Department of Molecular Biology, The Scripps Research Institute, La Jolla, California; ² Sydney Kimmel Cancer Center, San Diego, California; and Departments of ³ Obstetrics and Gynecology and ⁴ Medical Statistics, Informatics, and Health Economics, Innsbruck Medical University, Innsbruck, Austria

Requests for reprints: Steven I. Reed, Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037. Phone: 858-784-9836; Fax: 858-784-2781; E-mail: sreed{at}scripps.edu.

Cyclin E1 regulates the initiation of the S phase program in the mammalian cell division cycle. In normal cells, cyclin E1 protein expression is tightly controlled through a combination of transcriptional and proteolytic regulatory processes. However, in many types of human tumor, cyclin E1 expression is frequently dysregulated, including overexpression, nonperiodic expression relative to cell division, and generation of low molecular weight (LMW) derivatives. LMW derivatives of cyclin E1 have been proposed to be generated by the in vivo proteolytic cleavage of the full-length cyclin E1 protein by a yet to be identified tumor-specific protease. Recently, it was suggested that overexpression of full-length or LMW derivatives of cyclin E1 are independent variables associated with poor outcome in patients with breast cancer. However, we have extensively analyzed cyclin E1 protein expression in primary breast tumors and breast tumor-derived cell lines and found that the ability to detect LMW derivatives of cyclin E1 correlates only with the level of cyclin E1 protein. When cyclin E1 levels on Western blots are normalized, LMW derivatives of cyclin E1 were observed at roughly equal levels in all primary breast tumors, breast tumor-derived cell lines, immortalized nontransformed human mammary epithelial cells, and normal breast tissue. Therefore, the detection of LMW derivatives of cyclin E1 is likely a function of cyclin E1 protein levels, and the activity of the proteolytic machinery responsible for their generation is not a tumor-specific property. (Cancer Res 2006; 66(14): 7355-60)

This article has been cited by other articles:

				E. Sotillo, J. Garriga, A. Kurimchak, and X. Grana Cyclin E and SV40 Small t Antigen Cooperate to Bypass Quiescence and Contribute to Transformation by Activating CDK2 in Human Fibroblasts J. Biol. Chem., April 25, 2008; 283(17): 11280 - 11292. [Abstract] [Full Text] [PDF]

				J. M. Schildkraut, P. G. Moorman, A. E. Bland, S. Halabi, B. Calingaert, R. Whitaker, P. S. Lee, T. Elkins-Williams, R. C. Bentley, J. R. Marks, et al. Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 585 - 593. [Abstract] [Full Text] [PDF]

				S. Akli, C. S. Van Pelt, T. Bui, A. S. Multani, S. Chang, D. Johnson, S. Tucker, and K. Keyomarsi Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway Cancer Res., August 1, 2007; 67(15): 7212 - 7222. [Abstract] [Full Text] [PDF]